PD-1-Inhibitor-1 |cas 1673534-76-3|WO 2015033299
DC Chemicals, Website: www.dcchemicals.com
Product Name: PD-1-IN-1|Cas Number: 1673534-76-3| Catalog Number: DC10330
PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1) extracted from patent WO 2015033299 A1, compound example 4.
2017年11月30日星期四
Glucagon|cas 16941-32-5
Glucagon|cas 16941-32-5
DC Chemicals, Website: www.dcchemicals.com
Product Name: Glucagon|Cas Number: 16941-32-5| Catalog Number: DC10329|Other Nmaes: Porcine glucagon
Glucagon is a peptide hormone, exhibits therapeutic potential for metabolic disease.
DC Chemicals, Website: www.dcchemicals.com
Product Name: Glucagon|Cas Number: 16941-32-5| Catalog Number: DC10329|Other Nmaes: Porcine glucagon
Glucagon is a peptide hormone, exhibits therapeutic potential for metabolic disease.
Migalastat hydrochloride|cas 75172-81-5
Migalastat hydrochloride|cas 75172-81-5
DC Chemicals, Website: www.dcchemicals.com
Product Name: Migalastat hydrochloride|Cas Number: 75172-81-5| Catalog Number: DC10328|Other Nmaes: 1-Deoxygalactonojirimycin hydrochloride
Migalastat hydrochloride (1-Deoxygalactonojirimycin hydrochloride) is a potent and competitive inhibitor of α-galactosidase A (α-Gal A) with an IC50 of 0.04 μM for human α-Gal A.
Both IC50 and Ki values of migalastat hydrochloride toward human lysosomal a-Gal A are 0.04 μM[1].Fabry disease is an X-linked recessive disorder caused by the deficient activity of α-galactosidase A. α-Gal A activity in heart, kidney, spleen, and liver is increased dose- and time-dependently in transgenic mice that express human mutant alpha-Gal A with migalastat hydrochloride treatment. The half-life of DGJ is less than 1 day in all major issues and that of the enzyme synthesized during the DGJ treatment period is approximately 4 days[2]. Oral administration of migalastat hydrochloride reduces tissue GL-3 in fabry transgenic mice, and in urine and kidneys of some FD patients. Oral administration of migalastat hydrochloride to transgenic mice reduces elevated lyso-Gb3 levels up to 64%, 59%, and 81% in kidney, heart, and skin, respectively, generally equal to or greater than observed for GL-3[3].
DC Chemicals, Website: www.dcchemicals.com
Product Name: Migalastat hydrochloride|Cas Number: 75172-81-5| Catalog Number: DC10328|Other Nmaes: 1-Deoxygalactonojirimycin hydrochloride
Migalastat hydrochloride (1-Deoxygalactonojirimycin hydrochloride) is a potent and competitive inhibitor of α-galactosidase A (α-Gal A) with an IC50 of 0.04 μM for human α-Gal A.
Both IC50 and Ki values of migalastat hydrochloride toward human lysosomal a-Gal A are 0.04 μM[1].Fabry disease is an X-linked recessive disorder caused by the deficient activity of α-galactosidase A. α-Gal A activity in heart, kidney, spleen, and liver is increased dose- and time-dependently in transgenic mice that express human mutant alpha-Gal A with migalastat hydrochloride treatment. The half-life of DGJ is less than 1 day in all major issues and that of the enzyme synthesized during the DGJ treatment period is approximately 4 days[2]. Oral administration of migalastat hydrochloride reduces tissue GL-3 in fabry transgenic mice, and in urine and kidneys of some FD patients. Oral administration of migalastat hydrochloride to transgenic mice reduces elevated lyso-Gb3 levels up to 64%, 59%, and 81% in kidney, heart, and skin, respectively, generally equal to or greater than observed for GL-3[3].
2017年11月29日星期三
Calcitonin salmon|cas 47931-85-1
Calcitonin salmon|cas 47931-85-1
DC Chemicals, Website: www.dcchemicals.com
Product Name: Calcitonin salmon|Cas Number: 47931-85-1| Catalog Number: DC10327|Other Nmaes: Salmon calcitonin
Calcitonin, Salmon is a calcium regulating hormone secreted from mammalian thyroid parafollicular cells and in non-mammalian species from the ultimobranchial gland.
DC Chemicals, Website: www.dcchemicals.com
Product Name: Calcitonin salmon|Cas Number: 47931-85-1| Catalog Number: DC10327|Other Nmaes: Salmon calcitonin
Calcitonin, Salmon is a calcium regulating hormone secreted from mammalian thyroid parafollicular cells and in non-mammalian species from the ultimobranchial gland.
Mozavaptan |cas 137975-06-5
Mozavaptan |cas 137975-06-5
DC Chemicals, Website: www.dcchemicals.com
Product Name: Mozavaptan|Cas Number: 137975-06-5| Catalog Number: DC10326|Other Nmaes: OPC-31260; OPC31260l; OPC 31260
Mozavaptan (OPC31260) is a orally effective, nonpeptide vasopressin V2 receptor antagonist with an IC50 of 14 nM.
Mozavaptan causes a competitive displacement of [3H]-arginine vasopressin (AVP) binding to both V1 and V2 receptors with IC50 values of 1.2 μM and 14 nM, respectively. The Kd of [3H]-AVP is reduced significantly in both rat liver and kidney in the presence of mozavaptan (Kd=1.1 nM in liver, Kd=1.38 nM in kidney)[1].Mozavaptan at doses of 10 to 100 μg/kg, i.v., inhibits the antidiuretic action of exogenously administered arginine vasopressin in water-loaded, alcohol-anaesthetized rats in a dose-dependent manner. Mozavaptan does not exert an antidiuretic activity suggesting that it is not a partial V2 receptor agonist. Mozavaptan dose-dependently increases urine flow and decreases urine osmolality after oral administration at doses of 1 to 30 mg/kg in normal conscious rats[1].
DC Chemicals, Website: www.dcchemicals.com
Product Name: Mozavaptan|Cas Number: 137975-06-5| Catalog Number: DC10326|Other Nmaes: OPC-31260; OPC31260l; OPC 31260
Mozavaptan (OPC31260) is a orally effective, nonpeptide vasopressin V2 receptor antagonist with an IC50 of 14 nM.
Mozavaptan causes a competitive displacement of [3H]-arginine vasopressin (AVP) binding to both V1 and V2 receptors with IC50 values of 1.2 μM and 14 nM, respectively. The Kd of [3H]-AVP is reduced significantly in both rat liver and kidney in the presence of mozavaptan (Kd=1.1 nM in liver, Kd=1.38 nM in kidney)[1].Mozavaptan at doses of 10 to 100 μg/kg, i.v., inhibits the antidiuretic action of exogenously administered arginine vasopressin in water-loaded, alcohol-anaesthetized rats in a dose-dependent manner. Mozavaptan does not exert an antidiuretic activity suggesting that it is not a partial V2 receptor agonist. Mozavaptan dose-dependently increases urine flow and decreases urine osmolality after oral administration at doses of 1 to 30 mg/kg in normal conscious rats[1].
Aviptadil|cas 40077-57-4
Aviptadil|cas 40077-57-4
DC Chemicals, Website: www.dcchemicals.com
Product Name: Aviptadil|Cas Number: 40077-57-4| Catalog Number: DC10325|Other Nmaes: Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)
Aviptadil (INN) is an analog of vasoactive intestinal polypeptide (VIP) for the treatment of erectile dysfunction.
DC Chemicals, Website: www.dcchemicals.com
Product Name: Aviptadil|Cas Number: 40077-57-4| Catalog Number: DC10325|Other Nmaes: Vasoactive Intestinal Peptide (human, rat, mouse, rabbit, canine, porcine)
Aviptadil (INN) is an analog of vasoactive intestinal polypeptide (VIP) for the treatment of erectile dysfunction.
Omapatrilat |cas 167305-00-2
Omapatrilat |cas 167305-00-2
DC Chemicals, Website: www.dcchemicals.com
Product Name: Omapatrilat|Cas Number: 167305-00-2| Catalog Number: DC10324|Other Nmaes: BMS-186716
Omapatrilat is a dual inhibitor of the metalloproteases ACE and NEP with Ki values of 0.64 and 0.45 nM, respectively.
Omapatrilat exhibits high potency for NEP, NEP2 and ACE, moderate strong activity against APP, but low activity against ECE1 (Ki=0.45, 25, 0.64, 250 nM) [1]. In vitro autoradiography using the specific NEP inhibitor radioligand 125I-RB104 and the specific ACE inhibitor radioligand 125I-MK351A show omapatril at (10 mg/kg) causes rapid and potent inhibition of renal NEP and ACE, respectively, for 24 h[4].Omapatrilat demonstrates excellent blood pressure lowering in a variety of animal models characterized by various levels of plasma renin activity and significantly potentiates urinary sodium, ANP, and cGMP excretion in a cynomolgus monkey assay. Omapatrilat decreases mean arterial pressure (MAP) approximately 40 mmHg below baseline from 10 to 24 h. Oral administration of omapatrilat at 100 μM/kg once daily results in a 38 mmHg decrease in systolic blood pressure at day three as compared to vehicle [2]. Omapatrilat is widely used in experimental protocols related to hypertension and heart failure. Chronic oral administration of omapatrilat reduces aortic leakiness and atheroma formation with enhanced endothelial independent vasorelaxation to ANP[3]. Omapatrilat causes significant inhibition of plasma ACE and increased plasma renin activity in rats[4].
DC Chemicals, Website: www.dcchemicals.com
Product Name: Omapatrilat|Cas Number: 167305-00-2| Catalog Number: DC10324|Other Nmaes: BMS-186716
Omapatrilat is a dual inhibitor of the metalloproteases ACE and NEP with Ki values of 0.64 and 0.45 nM, respectively.
Omapatrilat exhibits high potency for NEP, NEP2 and ACE, moderate strong activity against APP, but low activity against ECE1 (Ki=0.45, 25, 0.64, 250 nM) [1]. In vitro autoradiography using the specific NEP inhibitor radioligand 125I-RB104 and the specific ACE inhibitor radioligand 125I-MK351A show omapatril at (10 mg/kg) causes rapid and potent inhibition of renal NEP and ACE, respectively, for 24 h[4].Omapatrilat demonstrates excellent blood pressure lowering in a variety of animal models characterized by various levels of plasma renin activity and significantly potentiates urinary sodium, ANP, and cGMP excretion in a cynomolgus monkey assay. Omapatrilat decreases mean arterial pressure (MAP) approximately 40 mmHg below baseline from 10 to 24 h. Oral administration of omapatrilat at 100 μM/kg once daily results in a 38 mmHg decrease in systolic blood pressure at day three as compared to vehicle [2]. Omapatrilat is widely used in experimental protocols related to hypertension and heart failure. Chronic oral administration of omapatrilat reduces aortic leakiness and atheroma formation with enhanced endothelial independent vasorelaxation to ANP[3]. Omapatrilat causes significant inhibition of plasma ACE and increased plasma renin activity in rats[4].
订阅：
博文 (Atom)